Trial Profile

A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 20 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SXRN (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Jiangsu Nutai Biologics

Most Recent Events

15 May 2026 Protocol was amended to add a continuous dosing exploration cohort, design changed from open-label to double blind, treatment arm was added.
15 May 2026 Planned End Date changed from 30 Apr 2026 to 9 Dec 2027.
15 May 2026 Planned primary completion date changed from 28 Feb 2026 to 6 Oct 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com